Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease-Reference-Cited by-同舟云学术

Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease

Published:2020-05-01 Issue:1 Volume:374 Page:113-125
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Waters Susanna^ORCID,Sonesson Clas,Svensson Peder^ORCID,Tedroff Joakim,Carta Manolo,Ljung Elisabeth,Gunnergren Jenny,Edling Malin,Svanberg Boel,Fagerberg Anne,Kullingsjö Johan,Hjorth Stephan,Waters Nicholas

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference57 articles.

1. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature

2. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission

3. Ballesteros JA Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors, in Methods in Neurosciences ( Sealfon SC 366–428, Academic Press, San Diego, CA.

4. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

5. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IRL790 modulated striatal D1 neurons synaptic plasticity ameliorating levodopa-induced dyskinesia in mouse;Frontiers in Aging Neuroscience;2024-05-30

2. Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis;Neurotherapeutics;2024-03

3. Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?;Expert Opinion on Pharmacotherapy;2023-12-27

4. Parkinson’s disease therapy: what lies ahead?;Journal of Neural Transmission;2023-05-05

5. Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics;Frontiers in Neuroscience;2023-01-09